EA201792545A1 - Способы и наборы для лечения депрессии - Google Patents

Способы и наборы для лечения депрессии

Info

Publication number
EA201792545A1
EA201792545A1 EA201792545A EA201792545A EA201792545A1 EA 201792545 A1 EA201792545 A1 EA 201792545A1 EA 201792545 A EA201792545 A EA 201792545A EA 201792545 A EA201792545 A EA 201792545A EA 201792545 A1 EA201792545 A1 EA 201792545A1
Authority
EA
Eurasian Patent Office
Prior art keywords
depression
kits
methods
treatment
treating depression
Prior art date
Application number
EA201792545A
Other languages
English (en)
Inventor
Джаскаран Сингх
Иво Каэрс
Элла Дали
Уэйн С. Дриветс
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201792545A1 publication Critical patent/EA201792545A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Emergency Medicine (AREA)

Abstract

Настоящее изобретение относится, в частности, к способам и наборам для лечения депрессии (предпочтительно устойчивой к лечению депрессии) или для лечения депрессии у пациентов с суицидальными наклонностями и/или для лечения и/или профилактики суицидального поведения (например, вынашивания идеи самоубийства), включающим прием эскетамина в соответствии с определенными режимами дозирования.
EA201792545A 2015-05-20 2016-05-20 Способы и наборы для лечения депрессии EA201792545A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562164026P 2015-05-20 2015-05-20
PCT/US2016/033404 WO2016187491A1 (en) 2015-05-20 2016-05-20 Methods and kits for treating depression

Publications (1)

Publication Number Publication Date
EA201792545A1 true EA201792545A1 (ru) 2018-05-31

Family

ID=57320901

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792545A EA201792545A1 (ru) 2015-05-20 2016-05-20 Способы и наборы для лечения депрессии

Country Status (20)

Country Link
US (1) US20160338977A1 (ru)
EP (1) EP3297618A4 (ru)
JP (1) JP2018515557A (ru)
KR (1) KR20180008634A (ru)
CN (1) CN107735081A (ru)
AU (3) AU2016263598A1 (ru)
CA (1) CA2986477A1 (ru)
CL (1) CL2017002904A1 (ru)
CO (1) CO2017011564A2 (ru)
DO (1) DOP2017000268A (ru)
EA (1) EA201792545A1 (ru)
EC (1) ECSP17077930A (ru)
GT (1) GT201700246A (ru)
HK (1) HK1252937A1 (ru)
IL (1) IL255463A (ru)
MA (1) MA42135A (ru)
MX (1) MX2017014797A (ru)
PE (1) PE20180260A1 (ru)
PH (1) PH12017502103A1 (ru)
WO (1) WO2016187491A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3636251B1 (en) 2013-03-15 2022-01-19 Janssen Pharmaceutica NV Pharmaceutical composition of s-ketamine hydrochloride
MA40462A (fr) 2014-08-13 2017-06-21 Janssen Pharmaceutica Nv Méthode de traitement de la dépression
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11707440B2 (en) * 2017-12-22 2023-07-25 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
CA3103440A1 (en) * 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
EP3628313A1 (en) 2018-09-28 2020-04-01 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration
WO2020070706A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
EP3860579A1 (en) * 2018-10-05 2021-08-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070547A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US20210378989A1 (en) * 2018-10-11 2021-12-09 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
US20230117657A1 (en) * 2019-03-05 2023-04-20 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
CN114286674A (zh) * 2019-08-28 2022-04-05 杨森制药公司 用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785500B2 (en) * 2006-03-22 2014-07-22 Icahn School Of Medicine At Mount Sinai Intranasal administration of ketamine to treat depression
MX2014010939A (es) * 2012-03-12 2014-11-13 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
WO2014169272A1 (en) * 2013-04-12 2014-10-16 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
KR20170054470A (ko) * 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법

Also Published As

Publication number Publication date
HK1252937A1 (zh) 2019-06-06
PE20180260A1 (es) 2018-02-05
EP3297618A1 (en) 2018-03-28
AU2021215155A1 (en) 2021-09-02
CL2017002904A1 (es) 2018-04-20
GT201700246A (es) 2019-07-29
JP2018515557A (ja) 2018-06-14
AU2016263598A1 (en) 2017-11-23
MX2017014797A (es) 2018-02-15
KR20180008634A (ko) 2018-01-24
CO2017011564A2 (es) 2018-04-19
DOP2017000268A (es) 2018-04-15
IL255463A (en) 2018-01-31
EP3297618A4 (en) 2019-01-23
CN107735081A (zh) 2018-02-23
AU2016263598A8 (en) 2017-11-30
AU2023237026A1 (en) 2023-10-12
MA42135A (fr) 2018-03-28
PH12017502103A1 (en) 2018-05-07
WO2016187491A1 (en) 2016-11-24
CA2986477A1 (en) 2016-11-24
ECSP17077930A (es) 2018-02-28
US20160338977A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
EA201792545A1 (ru) Способы и наборы для лечения депрессии
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
EA201691877A1 (ru) Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
EA201792182A1 (ru) Композиции и способы для лечения анемии
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
EA201592203A1 (ru) Способы лечения таупатии
MA40620A (fr) Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
EA201892287A1 (ru) Фармацевтические комбинации для лечения рака
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
MX2018001369A (es) Combinaciones de inhibidores de tirosina quinasa de bruton y sus usos.
BR112019008241A2 (pt) tratamento do prurigo nodular